Rivaroxaban
From Wikipedia, the free encyclopedia
 |
|
|
Rivaroxaban
|
|
| Systematic (IUPAC) name | |
| 5-chloro-N-[[2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]oxazolidin-5-yl]methyl] thiophene-2-carboxamide |
|
| Identifiers | |
| CAS number | 366789-02-8 |
| ATC code | ? |
| PubChem | 6433119 |
| Chemical data | |
| Formula | C19H18ClN3O5S |
| Mol. weight | 435.882 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 5.7-9.2 |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
?? |
| Legal status |
?? |
| Routes | oral |
Rivaroxaban (also known as BAY 59-7939) is an oral anticoagulant under development by Bayer. It acts by inhibiting the active form of coagulation factor X (factor Xa).
Contents |
[edit] Development
Rivaroxaban is an oxazolidinone derivative optimised for binding with factor Xa.[1] If marketed, it will be a joint product by Bayer and Ortho-McNeil Pharmaceutical.[2]
[edit] Uses
[edit] Expected
Due to the decreased need for monitoring, rivaroxaban is speculated to replace warfarin for a number of indications, such as atrial fibrillation.
[edit] Trial results
In phase IIb trials it was effective in reducing thromboembolic complications (deep vein thrombosis and pulmonary embolism) after orthopedic surgery[3] and it is under investigation for the treatment of DVT and PE and for anticoagulation in atrial fibrillation. Advantages are the oral administration (a benefit over low molecular weight heparins, which require subcutaneous injections) and no need for monitoring (an advantage over warfarin). In studies, dosages of 2.5-10 mg once or twice daily were used.
[edit] Related drugs
Ximelagatran, a direct thrombin inhibitor, was not marketed further due to its potential side-effects; the related compound dabigatran is undergoing studies. Together with rivaroxaban, LY517717 (Lilly) is under development as a non-monitored antithrombotic drug.[4]
[edit] Reference
- ^ Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005;48:5900-8. PMID 16161994.
- ^ Bayer, Ortho-McNeil to co-develop key thrombosis drug.
- ^ Erikkson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P, ODIXa-Hip study investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-8. PMID 16409461.
- ^ Hampton T. New oral anticoagulants show promise. JAMA 2006;295:743-4. PMID 16478891.
